Immunotherapy Drugs Market: By Drugs (Vaccines (Preventive Vaccines, Therapeutic Vaccines), Monoclonal Antibodies, Interferons Alpha & Beta, Checkpoint Inhibitors, Interleukins, and Others), By Therapy Area (Autoimmune & Inflammatory Diseases, Cancer, Infectious Diseases, and Others), By End User (Hospitals/Clinics, Cancer Research Centre, and Others), and Geography    

Purchase Option

$ 4400
$ 6600
$ 8900

Immunotherapy Drugs Market size was valued at USD 159.13 billion in 2022 and is projected to reach USD 355.34 Billion by 2029, growing at a CAGR of 10.4% from 2023 to 2029 due to surge in the prevalence of chronic diseases. According to International Agency for Research on Cancer (IACR) in 2018, 18.1 Mn people are estimated to be suffering from cancer worldwide, which is expected to reach 29.5 Mn by 2040. Moreover, the rising demand and development of monoclonal antibodies (mAbs) and the emergence of biosimilars are the major factors that are driving the growth of the immunotherapy drugs market. Additionally, favorable reimbursement policies and support by the government fuel the growth of the market. However, the High cost of treatment for chronic diseases hinders the growth of the market over the forecast period. The global immunotherapy drugs market is surging owing to strategic collaborations and definitive agreements between the market players to develop and commercialize products in the market.

Immunotherapy Drugs Market Key Developments:
  • In March 2018, Inovio collaborated with ApolloBio Corp, and provided exclusive right to develop, manufacture and commercialize VGX-3100, a DNA immunotherapy, in greater China.
  • In March 2018, Novartis collaborated with Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop next generation biomaterials systems to deliver immune-oncology therapies.

Global Immunotherapy Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

10.4%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Immunotherapy Drugs Market Dynamics

Rising adoption of targeted therapies and quick drug approval processes and rising prevalence rate of lifestyle diseases drives the growth of the market for Immunotherapy drugs. Cancer segment is the fastest growing segment by therapy area owing to increasing prevalence of cancer and the preference of immunotherapy as the first line of treatment for cancer. Rising demand for monoclonal antibodies and development of monoclonal antibodies coupled with the emergence of new biosimilars into the market enhances the growth of the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Immunotherapy Drugs Market Segmentation

By Drugs
  • Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Monoclonal Antibodies
  • Interferons Alpha & Beta
  • Checkpoint Inhibitors
  • Interleukins
  • Others
By Therapy Area
  • Autoimmune & Inflammatory Diseases
  • Cancer
  • Infectious Diseases
  • Others
By End User
  • Hospitals/Clinics
  • Cancer Research Centers
  • Others
By Geography

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Frequently Asked Questions

The immunotherapy drugs market size was valued at USD 159.13 billion in 2022

The immunotherapy drugs market key players are: Pfizer Inc AstraZeneca Johnson & Johnson Novartis International AG GlaxoSmithKline Plc Merck & Co AbbVie Inc Immatics Biotechnologies Amgen Inc. Hoffmann-La Roche Ltd

The immunotherapy drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

1. Executive Summary
2. Global Immunotherapy Drugs Market Introduction
2.1. Global Immunotherapy Drugs Market Taxonomy
2.2. Global Immunotherapy Drugs Market Definitions
2.2.1. By Type
2.2.2. By Application
2.2.3. By End User
2.2.4. By Region
3. Global Immunotherapy Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Immunotherapy Drugs Market Dynamic Factors - Impact Analysis
3.6. Global Immunotherapy Drugs Market Competition Landscape
4. Global Immunotherapy Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Immunotherapy Drugs Market, By Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1. Checkpoint Inhibitors (CI)
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Monoclonal Antibodies (mAbs)
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Interferons & Interleukins (IFs & ILs)
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Immunotherapy Drugs Market, By Application, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1. Cancer
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Autoimmune & Inflammatory Diseases
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Infectious Diseases
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Immunotherapy Drugs Market, By End User, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1. Hospitals
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Clinics
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Immunotherapy Drugs Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Region, 2023 - 2029
9. North America Immunotherapy Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Checkpoint Inhibitors (CI)
9.1.2. Monoclonal Antibodies (mAbs)
9.1.3. Interferons & Interleukins (IFs & ILs)
9.1.4. Others
9.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Cancer
9.2.2. Autoimmune & Inflammatory Diseases
9.2.3. Infectious Diseasess
9.2.4. Others
9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2023 - 2029
9.6. North America Immunotherapy Drugs Market Dynamics Trends
10. Europe Immunotherapy Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
10.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Checkpoint Inhibitors (CI)
10.1.2. Monoclonal Antibodies (mAbs)
10.1.3. Interferons & Interleukins (IFs & ILs)
10.1.4. Others
10.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Cancer
10.2.2. Autoimmune & Inflammatory Diseases
10.2.3. Infectious Diseasess
10.2.4. Others
10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Others
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2023 - 2029
10.6. Europe Immunotherapy Drugs Market Dynamics  Trends
11. Asia-Pacific Immunotherapy Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
11.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Checkpoint Inhibitors (CI)
11.1.2. Monoclonal Antibodies (mAbs)
11.1.3. Interferons & Interleukins (IFs & ILs)
11.1.4. Others
11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Cancer
11.2.2. Autoimmune & Inflammatory Diseases
11.2.3. Infectious Diseasess
11.2.4. Others
11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Others
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2023 - 2029
11.6. Asia-Pacific Immunotherapy Drugs Market Dynamics Trends
12. Latin America Immunotherapy Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
12.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Checkpoint Inhibitors (CI)
12.1.2. Monoclonal Antibodies (mAbs)
12.1.3. Interferons & Interleukins (IFs & ILs)
12.1.4. Others
12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Cancer
12.2.2. Autoimmune & Inflammatory Diseases
12.2.3. Infectious Diseasess
12.2.4. Others
12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Others
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2023 - 2029
12.6. Latin America Immunotherapy Drugs Market Dynamics Trends
13. Middle East and Africa Immunotherapy Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
13.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Checkpoint Inhibitors (CI)
13.1.2. Monoclonal Antibodies (mAbs)
13.1.3. Interferons & Interleukins (IFs & ILs)
13.1.4. Others
13.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Cancer
13.2.2. Autoimmune & Inflammatory Diseases
13.2.3. Infectious Diseasess
13.2.4. Others
13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Others
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. MEA Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2023 - 2029
13.6. MEA Immunotherapy Drugs Market Dynamics Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Pfizer Inc
14.2.2. AstraZeneca
14.2.3. Johnson & Johnson
14.2.4. Novartis International AG
14.2.5. GlaxoSmithKline Plc
14.2.6. Merck & Co
14.2.7. AbbVie Inc
14.2.8. Immatics Biotechnologies
14.2.9.  Amgen Inc.
14.2.10. F. Hoffmann-La Roche Ltd
15. Research Methodology
16. Key Assumptions and Acronyms
 
  • Pfizer Inc
  • AstraZeneca
  • Johnson & Johnson
  • Novartis International AG
  • GlaxoSmithKline Plc
  • Merck & Co
  • AbbVie Inc
  • Immatics Biotechnologies
  • Amgen Inc.
  • Hoffmann-La Roche Ltd